Serological Markers Associated with Different Clinical Stages in Patients with HBV Infection
Viral markers of hepatitis B in serum may be valuable in predicting outcomes such as deaths due to liver cirrhosis and development of hepatocellular carcinoma. The frequency of these markers was detected in various stages of chronic hepatitis B infection. Methods- This was a prospective study of 1450 patients enrolled to identify the frequency of HBV serological markers. All the specimens were tested by Enzyme linked Immuno-sorbent assay (ELISA) and data was analyzed by statistical software SPSS 20.0. Results- Out of 1450 patients, 3.44% were HBsAg positive and isolated anti-HBc IgM positivity was seen in 1.03% of the population. Out of 1450 specimens, 3.1% turned positive for HBeAg and 0.96% showed anti HBe activity. In addition, 16.2% (n = 235) of the participants possessed anti-HBs antibodies resulting from vaccinations, while 83.79% (n = 1215) had no detectable anti HBs antibodies. Acute HBV infection was present in 1.03% of the patient population, while 2.4% of patients were found to be suffering from chronic HBV infection with liver cirrhosis. Conclusion- Hepatitis B viral markers must be used in conjunction with routine laboratory tests for clinical assessment of patients and together, the information would be useful for the identification of patients who would require close monitoring and those who would need antiviral therapy.
Key words - Hepatitis, Hepatitis B virus, Serological markers, Enzyme linked immune-sorbent assay.